

**BETA ARRESTİN
PROTEİNLERİ VE KANSER**

Saber YARI BOSTANABAD

© Copyright 2020

Bu kitabın, basım, yayın ve satış hakları Akademisyen Kitabevi A.Ş.'ne aittir. Anılan kuruluşun izni alınmadan kitabın tümü ya da bölümleri mekanik, elektronik, fotokopi, manyetik kağıt ve/veya başka yöntemlerle çoğaltılamaz, basılamaz, dağıtılamaz. Tablo, şekil ve grafikler izin alınmadan, ticari amaçlı kullanılamaz. Bu kitap T.C. Kültür Bakanlığı bandrolü ile satılmaktadır.

ISBN

978-625-7679-57-2

Kitap Adı

Beta Arrestin Proteinleri ve Kanser

Yazar

Saber YARI BOSTANABAD

Yayın Koordinatörü

Yasin Dilmen

Sayfa ve Kapak Tasarımı

Akademisyen Dizgi Ünitesi

Yayıncı Sertifika No

47518

Baskı ve Cilt

Vadi Matbaacılık

Bisac Code

MED062010

DOI

10.37609/akya.111

GENEL DAĞITIM

Akademisyen Kitabevi A.Ş.

Halk Sokak 5 / A

Yenişehir / Ankara

Tel: 0312 431 16 33

siparis@akademisyen.com

www.akademisyen.com

İÇİNDEKİLER

Giriş	1
KURAMSAL TEMELLER	2
1.1. Memenin anatomisi	3
1.2. Meme Kanserinin Tanımı.....	3
1.3. Meme kanseri risk faktörleri.....	4
1.3.1. CİNSİYET.....	5
1.3.2. YAŞ	5
1.3.3. ETNİK KÖKEN	5
1.3.4. AİLE ÖYKÜSÜ	5
1.3.5. Çevresel Faktörler ve Yaşam Tarzı.....	6
1.3.5.1. Obezite	6
1.3.5.2. Fiziksel Aktivite	6
1.3.5.3. Radyasyon	6
1.3.6. Genetik faktörler.....	7
1.4. Meme kanseri alt tipleri ve sınıflandırılması	7
1.3.7. Histopatolojik Sınıflandırılma	7
1.4.1.1. Karsinoma İn Situ.....	8
1.4.1.2. İnvaziv Karsinoma.....	8
1.3.8. Moleküler alt tipler	9
1.4. ÜÇLÜ NEGATİF MEME KANSERLERİ.....	10
1.4.1. Üçlü-Negatif meme kanseri hücre hattı modelleri	12
1.4.2. HÜCRE HATLARI VE ÖZELLİKLERİ.....	14
1.5. Kolorektal KANSERİ	16
1.6. ARRESTİN PROTEİNLERİ	17
1.6.1. ARRESTİN TİPLERİ.....	18
1.6.2. BETA ARRESTİN PROTEİNLERİ	19
1.6.3. Beta Arrestinler ve G Protein-Kenetli Reseptör Regülasyonu	21
1.6.4. Klasik Sinyal Yolakları.....	21
1.6.5. Reseptör İnternalizasyonu	22

İçindekiler

1.6.6. Klasik Olmayan Sinyal Yolları.....	23
1.7. Kanserlerde Beta Arrestinlerin Rolü.....	24
1.8. BETA Arrestinler ve meme kanseri	26
1.8.1. Meme Kanserinde Beta Arrestin Seviyeleri	27
1.9. Beta Arrestin ve PROLİFERASYON.....	29
1.10. BETA Arrestinler ve Apoptosis	30
1.11. Beta Arrestin PROTEİLERİ ve İNVASYON, migration .	31
1.12. Beta Arrestin ve HÜCRE DÖNGÜSÜ	32
GEREKÇE VE AMAÇ.....	33
Yöntem	34
1.13. TCGA veri analizi.....	34
1.14. İstatistiksel analiz.....	34
SONUÇLAR.....	35
1.15. TCGA VERİ ANALİZİ.....	35
1.15.1. akciğer kanserlerinde BETA ARRESTİN 1 ve 2'lerin ifade düzeylerinin incelenmesi	35
1.15.2. MEME kanserlerinde BETA ARRESTİN 1 ve 2'lerin ifade düzeylerinin incelenmesi	36
1.15.3. KOLON VE REKTUM kanserlerinde BETA ARRESTİN 1 ve 2'lerin ifade düzeylerinin incelenmesi	38
1.15.4. MİDE KANSERLERİNDE BETA ARRESTİN 1 VE 2'LERİN İFADE DÜZEYLERİNİN İNCELENMESİ.....	39
1.15.5. KARACİĞER kanserlerinde BETA ARRESTİN 1 ve 2'lerin ifade düzeylerinin incelenmesi	41
TARTIŞMA VE SONUÇ	43
1.16. TARTIŞMA	43
1.17. SONUÇ.....	50
Kaynaklar	51

KAYNAKLAR

1. Kalimutho M, Nones K, Srihari S, Duijf PHG, Waddell N, Khanna KK. Patterns of Genomic Instability in Breast Cancer. *Trends Pharmacol Sci* [Internet]. 2019;40(3):198–211. Available from: <https://doi.org/10.1016/j.tips.2019.01.005>
2. Roche. Breast cancer A guide for journalists on breast cancer and its treatment. Roche. 2016;3–6.
3. World Health Organization (WHO). International Agency for Research on Cancer. Estimated age-standardized incidence rates (World) in 2018, all cancers, both sexes, all ages. GLOBOCAN Cancer Today [Internet]. 2018;2018. Available from: https://gco.iarc.fr/today/online-analysis-map?v=2018&mode=population&mode_population=-continents&population=900&populations=900&key=asr&sex=0&cancer=39&type=0&statistic=5&prevalence=0&population_group=0&ages_group%5B%5D=0&ages_group%5B%5D=17&nb_items=5&gro
4. Nounou MI, Elamrawy F, Ahmed N, Abdelraouf K, Goda S, Syed-Sha-Qhattal H. Breast cancer: Conventional diagnosis and treatment modalities and recent patents and technologies supplementary issue: Targeted therapies in breast cancer treatment. *Breast Cancer Basic Clin Res*. 2015;9:17–34.
5. Society AC. Breast Cancer. NCCN Guidel Breast Cancer Patients, 2017;(February):6.
6. Goldman M, Craft B, Hastie M, Repečka K, Kamath A, McDade F, et al. The UCSC Xena platform for public and private cancer genomics data visualization and interpretation. *bioRxiv*. 2018;326470.
7. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* [Internet]. 2018;68(6):394–424. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/30207593>
8. Tanis PJ, Nieweg OE, Valdés Olmos RA, Kroon BBR. Anatomy and physiology of lymphatic drainage of the breast from the perspective of sentinel node biopsy. *J Am Coll Surg*. 2001;192(3):399–409.
9. Aronson KJ, Miller AB, Wooleott CG, Sterns EE, McCready DR, Lickley LA, et al. Breast adipose tissue concentrations of polychlorinated biphenyls and other organochlorines and breast cancer risk. *Cancer Epidemiol Biomarkers Prev*. 2000;9(1):55–63.
10. Breast Cancer. 2018;
11. Alaa Alkhazraji, Mohamed Elgamal, Shi Hui Ang, Velizar Shivarov. All cancer hallmarks lead to diversity. *Int J Clin Exp Med*. 2019;12(1):132–57.
12. American Cancer Society. Cancer Facts & Figures 2018. 2018;
13. Wang C, Kar S, Lai X, Cai W, Arfuso F, Sethi G, et al. Triple negative breast cancer in Asia: An insider's view. *Cancer Treat Rev*. 2018;62:29–38.

Kaynaklar

14. ABDEL R. OMRAN. The Epidemiologic Transition: A Theory of the Epidemiology of Population Change. *Milbank Q* [Internet]. 2005;83(4):731–57. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2690264/pdf/milq0083-0398.pdf>
15. Gersten O, Wilmoth JR. The cancer transition in Japan since 1951. *Demogr Res.* 2002;7(August):271–306.
16. Giordano SH, Cohen DS, Buzdar AU, Perkins G, Hortobagyi GN. Breast carcinoma in men: A population-based study. *Cancer.* 2004;101(1):51–7.
17. Gross RE. Breast cancer: risk factors, screening, and prevention. *Semin Oncol Nurs* [Internet]. 2000;16(3):176–84. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/10967790>
18. Couto E, Hemminki K. Estimates of heritable and environmental components of familial breast cancer using family history information. *Br J Cancer.* 2007;96(11):1740–2.
19. La Vecchia C, Giordano SH, Hortobagyi GN, Chabner B. Overweight, Obesity, Diabetes, and Risk of Breast Cancer: Interlocking Pieces of the Puzzle. *Oncologist.* 2011;16(6):726–9.
20. Gunter MJ, Wang T, Cushman M, Xue X, Wassertheil-Smoller S, Strickler HD, et al. Circulating Adipokines and Inflammatory Markers and Postmenopausal Breast Cancer Risk. *J Natl Cancer Inst.* 2015;107(9):1–10.
21. Hildebrand JS, Gapstur SM, Campbell PT, Gaudet MM, Patel A V. Recreational physical activity and leisure-time sitting in relation to postmenopausal breast cancer risk. *Cancer Epidemiol Biomarkers Prev.* 2013;22(10):1906–12.
22. Little MP. Cancer and non-cancer effects in Japanese atomic bomb survivors. *J Radiol Prot.* 2009;29(2).
23. Moran MS. Radiation therapy in the locoregional treatment of triple-negative breast cancer. *Lancet Oncol* [Internet]. 2015;16(3):e113–22. Available from: [http://dx.doi.org/10.1016/S1470-2045\(14\)71104-0](http://dx.doi.org/10.1016/S1470-2045(14)71104-0)
24. Pillai S, Vakili-Azghandi M, Sandry R, Yin Lam AK, Nassiri M, Kooshyar MM, et al. Hereditary breast cancer; Genetic penetrance and current status with BRCA. *J Cell Physiol.* 2018;(August 2018):5741–50.
25. Turnbull C, Rahman N. Genetic Predisposition to Breast Cancer: Past, Present, and Future. *Annu Rev Genomics Hum Genet.* 2008;9(1):321–45.
26. Antoniou AC, Casadei S, Heikkinen T, Barrowdale D, Pylkas K, Roberts J, et al. Breast-Cancer Risk in Families With Mutations in PALB2 EDITORIAL COMMENT. *N Engl J Med.* 2014;371(6):497–506.
27. Spitale A, Mazzola P, Soldini D, Mazzucchelli L, Bordoni A. Breast cancer classification according to immunohistochemical markers : clinicopathologic features and short-term survival analysis in a population-based study from the South of Switzerland. 2009;(December 2008):628–35.
28. Kerlikowske K. Epidemiology of Ductal Carcinoma In Situ. 2010;139–41.
29. Arpino G, Bardou VJ, Clark GM, Elledge RM. Research article Infiltrating lobular carcinoma of the breast : tumor characteristics and clinical outcome. 2004;7–11.

30. Ahn SG, Kim SJ, Kim C, Jeong J. Molecular Classification of Triple-Negative Breast Cancer. *J Breast Cancer* [Internet]. 2016;19(3):223. Available from: <https://synapse.koreamed.org/DOIx.php?id=10.4048/jbc.2016.19.3.223>
31. Provenzano E, Ulaner GA. Molecular Classification of Breast Cancer. *Positron Emiss Tomogr* [Internet]. 2019;13(3):325–38. Available from: <https://doi.org/10.1016/j.cpet.2018.02.004>
32. Lehmann BD, Shyr Y, Pietenpol JA, Lehmann BD, Bauer JA, Chen X, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. *J Clin Invest*. 2011;121(7):2750–67.
33. Reen ANRG. Molecular classification of breast cancer : what the pathologist needs to know. 2017;49(February):111–9.
34. Yanagawa M, Ikemoto K, Kawauchi S, Furuya T, Yamamoto S, Oka M, et al. Luminal A and luminal B (HER2 negative) subtypes of breast cancer consist of a mixture of tumors with different genotype. *BMC Res Notes*. 2012;5.
35. Perou CM. Molecular Stratification of Triple-Negative Breast Cancers. *Oncologist* [Internet]. 2011;16(Supplement 1):61–70. Available from: <http://theoncologist.alphamedpress.org/cgi/doi/10.1634/theoncologist.2011-S1-61>
36. Riley MA, Wertz JE. *BACTERIOCINS : Evolution , Ecology , and Application*. 2002;
37. Denkert C, Liedtke C, Tutt A, von Minckwitz G. Molecular alterations in triple-negative breast cancer—the road to new treatment strategies. *Lancet* [Internet]. 2017;389(10087):2430–42. Available from: [http://dx.doi.org/10.1016/S0140-6736\(16\)32454-0](http://dx.doi.org/10.1016/S0140-6736(16)32454-0)
38. Anjum F, Razvi N, Masood MA. Breast Cancer Therapy: A Mini Review. *MOJ Drug Des Dev Ther*. 2017;1(2).
39. Reis-filho JS, Ph D. Triple-Negative Breast Cancer. 2010;
40. Uscanga-Perales GI, Santuario-Facio SK, Ortiz-López R. Triple negative breast cancer: Deciphering the biology and heterogeneity. *Med Univ* [Internet]. 2016;18(71):105–14. Available from: <http://linkinghub.elsevier.com/retrieve/pii/S1665579616300667>
41. Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L. Triple-negative breast cancer: Challenges and opportunities of a heterogeneous disease. *Nat Rev Clin Oncol* [Internet]. 2016;13(11):674–90. Available from: <http://dx.doi.org/10.1038/nrclinonc.2016.66>
42. Hwang S-Y, Park S, Kwon Y. Recent therapeutic trends and promising targets in triple negative breast cancer. *Pharmacol Ther* [Internet]. 2019; Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0163725819300208>
43. Lee A, Djamgoz MBA. Triple negative breast cancer: Emerging therapeutic modalities and novel combination therapies. *Cancer Treat Rev*. 2018;62:110–22.

44. Pareja F, Geyer FC, Marchiò C, Burke KA, Weigelt B, Reis-Filho JS. Triple-negative breast cancer: the importance of molecular and histologic subtyping, and recognition of low-grade variants. *npj Breast Cancer* [Internet]. 2016;2(1):16036. Available from: <http://www.nature.com/articles/npjbcancer201636>
45. Marotti JD, de Abreu FB, Wells WA, Tsongalis GJ. Triple-Negative Breast Cancer: Next-Generation Sequencing for Target Identification. *Am J Pathol* [Internet]. 2017;187(10):2133–8. Available from: <http://dx.doi.org/10.1016/j.ajpath.2017.05.018>
46. Garrido-castro AC, Lin NU, Polyak K. Insights into Molecular Classifications of Triple-Negative Breast Cancer : Improving Patient Selection for Treatment. 2019;(February).
47. Stefansson OA, Jonasson JG, Johannsson OT, Olafsdottir K, Steinarsdottir M, Valgeirsdottir S, et al. Genomic profiling of breast tumours in relation to BRCA abnormalities and phenotypes. *Breast Cancer Res*. 2009;11(4):1–14.
48. He J, Yang J, Chen W, Wu H, Yuan Z, Wang K, et al. Molecular features of triple negative breast cancer: Microarray evidence and further integrated analysis. *PLoS One*. 2015;10(6).
49. Hubalek M, Czech T, Müller H. Biological Subtypes of Triple-Negative Breast Cancer. *Breast Care*. 2017;12(1):8–14.
50. Lehmann BD, Jovanović B, Chen X, Estrada M V, Johnson KN, Shyr Y, et al. Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection. *PLoS One*. 2016;11(6):e0157368.
51. Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. *Cancer Epidemiol Biomarkers Prev*. 2010;19(8):1893–907.
52. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, et al. International association for the study of lung cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. *J Thorac Oncol* [Internet]. 2011;6(2):244–85. Available from: <http://dx.doi.org/10.1097/JTO.0b013e318206a221>
53. Burkitt DP. Epidemiology of cancer of the colon and rectum. *Dis Colon Rectum*. 1993;36(11):1071–82.
54. Montminy EM, Jang A, Conner M, Karlitz JJ. Screening for Colorectal Cancer. *Med Clin North Am* [Internet]. 2020;104(6):1023–36. Available from: <https://doi.org/10.1016/j.mcna.2020.08.004>
55. Cummings KM, Michalek A, Mettlin C, Mittelman A. Screening for colorectal cancer using the hemoccult II stool guaiac slide test. *Cancer*. 1984;53(10):2201–5.
56. Shamekhi S, Abdolalizadeh J, Ostadrahimi A, Mohammadi SA, Barzegari A, Lotfi H, et al. *ca. Probiotics Antimicrob Proteins*. 2020;12(1):311–9.

Kaynaklar

57. World Health Organization. All cancers. 2018;876:1–2. Available from: <https://gco.iarc.fr/today/data/factsheets/cancers/39-All-cancers-fact-sheet.pdf>
58. Moore M a., Eser S, Iginov N, Iginov S, Mohagheghi MA, Mousavi-Jarrahi A, et al. Cancer Epidemiology and Control in North-Western and Central Asia - Past, Present and Future. *Asian Pacific J Cancer Prev*. 2010;11:17–31.
59. Nuber S, Zabel U, Lorenz K, Nuber A, Milligan G, Tobin AB, et al. β -Arrestin biosensors reveal a rapid, receptor-dependent activation/deactivation cycle. 2016;531(7596):661–4.
60. Attramadal H, Arriza JL, Aoki C, Dawson TM, Codina J, Kwatra MM, et al. β -Arrestin2, a novel member of the arrestin/ β -arrestin gene family. *J Biol Chem*. 1992;267(25):17882–90.
61. Abe T, Yamaki K, Tsuda M, Singh VK, Suzuki S, Mckinnon R, et al. Rat pineal S-antigen : sequence analysis reveals presence of a-transducin homologous sequence. 1989;247(2):307–11.
62. Shukla AK, Manglik A, Kruse AC, Xiao K, Reis RI, Tseng WC, et al. Structure of active β -arrestin-1 bound to a G-protein-coupled receptor phosphopeptide. *Nature* [Internet]. 2013;497(7447):137–41. Available from: <http://dx.doi.org/10.1038/nature12120>
63. Isolation of retinal lymphocytes in experimental autoimmune uveoretinitis: Phenotypic and functional characterization. *Immunology*. 1993;78(3):393–8.
64. Stadel JM, Nambi P, Shorr RGL, Sawyer DF, Caron MG, Lefkowitz RJ. Catecholamine-induced desensitization of turkey erythrocyte adenylate cyclase is associated with phosphorylation of the. 1983;80(June):3173–7.
65. Natl MHP, Sci A, Natl IDP, Sci A, Strasser H, Sibley DR, et al. A Novel Catecholamine-Activated Adenosine Cyclic 3', 5' -Phosphate Independent Pathway for β -Adrenergic Receptor Phosphorylation in Wild-Type and Mutant S49 Lymphoma Cells : Mechanism of Homologous Desensitization of Adenylate. 1986;(1983):1371–7.
66. Luttrell LM, Ferguson SS, Daaka Y, Miller WE, Maudsley S, Della Rocca GJ, et al. β -arrestin-dependent formation of β 2 adrenergic receptor-*Src* protein kinase complexes. *Science* (80-) [Internet]. 1999;283(5402):655–61. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/9924018> <http://www.sciencemag.org/content/283/5402/655.full.pdf>
67. Wilden U, Hall SW, Kühn H. Phosphodiesterase activation by photoexcited rhodopsin is quenched when rhodopsin is phosphorylated and binds the intrinsic 48-kDa protein of rod outer segments. *Proc Natl Acad Sci U S A*. 1986;83(5):1174–8.
68. Lohse MJ, Benovic JL, Codina J, Caron MG, Lefkowitz RJ. I-Arrestin : A Protein That Regulates [I-Adrenergic. 1984;
69. Hirsch JA, Schubert C, Gurevich V V, Sigler PB. The 2.8 Å Crystal Structure of Visual Arrestin: A Model for Arrestin's Regulation. *Cell*. 1999;97:257–69.

Kaynaklar

70. Gurevich V V, Gurevich E V, Uversky VN. Arrestins: structural disorder creates rich functionality. *Protein Cell* [Internet]. 2018;1–18. Available from: <https://doi.org/10.1007/s13238-017-0501-8>
71. Lefkowitz RJ. Arrestins come of age: A personal historical perspective [Internet]. 1st ed. Vol. 118, *Progress in Molecular Biology and Translational Science*. Elsevier Inc.; 2013. 3–18 p. Available from: <http://dx.doi.org/10.1016/B978-0-12-394440-5.00001-2>
72. Gurevich E V, Gurevich V V. Arrestins: Ubiquitous regulators of cellular signaling pathways. *Genome Biol*. 2006;7(9).
73. Han M, Gurevich V V, Vishnivetskiy SA, Sigler PB, Schubert C. Crystal structure of beta-arrestin at 1.9 Å: possible mechanism of receptor binding and membrane Translocation. *Structure* [Internet]. 2001;9(9):869–80. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11566136%5Cn-http://ac.els-cdn.com/S096921260100644X/1-s2.0-S096921260100644X-main.pdf?_tid=34d6e796-92e1-11e2-8224-00000aacb361&acdnat=1363950852_147a0d21244dd88d0f0a36b7b8c56fee
74. Gu YJ, Sun WY, Zhang S, Wu JJ, Wei W. The emerging roles of β -arrestins in fibrotic diseases. *Acta Pharmacol Sin* [Internet]. 2015;36(11):1277–87. Available from: <http://dx.doi.org/10.1038/aps.2015.74>
75. Philipp M, Evron T, Caron MG. The role of arrestins in development. *Prog Mol Biol Transl Sci*. 2013;118:225–42.
76. Hamdan FF, Rochdi MD, Breton B, Fessart D, Michaud DE, Charest PG, et al. Unraveling G protein-coupled receptor endocytosis pathways using real-time monitoring of agonist-promoted interaction between β -arrestins and AP-2. *J Biol Chem*. 2007;282(40):29089–100.
77. Bayburt TH, Vishnivetskiy SA, McLean MA, Morizumi T, Huang CC, Tesmer JJJ, et al. Monomeric rhodopsin is sufficient for normal rhodopsin kinase (GRK1) phosphorylation and arrestin-1 binding. *J Biol Chem*. 2011;286(2):1420–8.
78. Fan H. β -Arrestins 1 and 2 are critical regulators of inflammation. *Innate Immun*. 2014;20(5):451–60.
79. McDonald PH. beta -Arrestin 2: A Receptor-Regulated MAPK Scaffold for the Activation of JNK3. *Science* (80-). 2000;290(5496):1574–7.
80. Luttrell LM, Lefkowitz RJ. The role of beta-arrestins in the termination and transduction of G-protein-coupled receptor signals. *Luttrell-Lefkowitz (se- cuencias LIEF-RXR)*. 2002;
81. Gurevich V V, Gurevich E V. The molecular acrobatics of arrestin activation. *Trends Pharmacol Sci*. 2004;25(2):105–11.
82. Barak LS, Ferguson SS, Zhang J, Caron MG. A beta-arrestin/green fluorescent protein biosensor for detecting G protein-coupled receptor activation. *J Biol Chem*. 1997;272(44):27497–500.
83. Goodman OB, Krupnick JG, Gurevich V V, Benovic JL, Keen JH. Arrestin / Clathrin Interaction. 1997;272(23):15017–22.

84. Laporte SA, Oakley RH, Holt JA, Barak LS, Caron MG. The interaction of β -arrestin with the AP-2 adaptor is required for the clustering of β 2-adrenergic receptor into clathrin-coated pits. *J Biol Chem*. 2000;275(30):23120–6.
85. Shenoy SK, Lefkowitz RJ. Shenoy & Lefkowitz, 2005. 2005;(14):1–22.
86. DeWire SM, Ahn S, Lefkowitz RJ, Shenoy SK. β -Arrestins and Cell Signaling. *Annu Rev Physiol* [Internet]. 2007;69(1):483–510. Available from: <http://www.annualreviews.org/doi/10.1146/annurev.physiol.69.022405.154749>
87. Rajagopal S, Kim J, Ahn S, Craig S, Lam CM, Gerard NP, et al. -arrestin- but not G protein-mediated signaling by the “decoy” receptor CXCR7. *Proc Natl Acad Sci* [Internet]. 2010;107(2):628–32. Available from: <http://www.pnas.org/cgi/doi/10.1073/pnas.0912852107>
88. Tohgo A, Choy EW, Gesty-Palmer D, Pierce KL, Laporte S, Oakley RH, et al. The stability of the G protein-coupled receptor- β -arrestin interaction determines the mechanism and functional consequence of ERK activation. *J Biol Chem*. 2003;278(8):6258–67.
89. Calebiro D, Nikolaev VO, Persani L, Lohse MJ. Signaling by internalized G-protein-coupled receptors. *Trends Pharmacol Sci* [Internet]. 2010;31(5):221–8. Available from: <http://dx.doi.org/10.1016/j.tips.2010.02.002>
90. Lohse MJ, Calebiro D. Receptor signals come in waves. *Nature*. 2013;495(7442):457–8.
91. Moore CAC, Milano SK, Benovic JL. Regulation of Receptor Trafficking by GRKs and Arrestins. *Annu Rev Physiol* [Internet]. 2007;69(1):451–82. Available from: <http://www.annualreviews.org/doi/10.1146/annurev.physiol.69.022405.154712>
92. Beaulieu JM, Caron MG. B-Arrestin Goes Nuclear. *Cell*. 2005;123(5):755–7.
93. Rosanò L, Cianfrocca R, Masi S, Spinella F, Di Castro V, Biroccio A, et al. Beta-arrestin links endothelin A receptor to beta-catenin signaling to induce ovarian cancer cell invasion and metastasis. *Proc Natl Acad Sci U S A*. 2009;106(8):2806–11.
94. Buchanan FG, Gorden DL, Matta P, Shi Q, Matrisian LM, DuBois RN. Role of beta-arrestin 1 in the metastatic progression of colorectal cancer. *Proc Natl Acad Sci U S A*. 2006;103(5):1492–7.
95. Bagnato A, Rosanò L. New Routes in GPCR / β -Arrestin- Driven Signaling in Cancer Progression and Metastasis. 2019;10(February).
96. Zhang Z, Hao J, Zhao Z, Ben P, Fang F, Shi L, et al. β -Arrestins facilitate ubiquitin-dependent degradation of apoptosis signal-regulating kinase 1 (ASK1) and attenuate H2O2-induced apoptosis. *Cell Signal* [Internet]. 2009;21(7):1195–206. Available from: <http://dx.doi.org/10.1016/j.cell-sig.2009.03.010>
97. Vines CM, Revankar CM, Maestas DC, LaRusch LL, Cimino DE, Kohout TA, et al. N-Formyl Peptide Receptors Internalize but Do Not Recycle in the Absence of Arrestins. *J Biol Chem*. 2003;278(43):41581–4.

Kaynaklar

98. Chen W, Hu LA, Semenov M V, Yanagawa S, Kikuchi A, Lefkowitz RJ, et al. B-Arrestin 1 Modulates Lymphoid Enhancer Factor Transcriptional Activity Through Interaction With Phosphorylated Dishevelled Proteins. *Proc Natl Acad Sci U S A*. 2001;98(26):14889–94.
99. Kang J, Shi Y, Xiang B, Qu B, Su W, Zhu M, et al. A nuclear function of β -arrestin1 in GPCR signaling: Regulation of histone acetylation and gene transcription. *Cell*. 2005;123(5):833–47.
100. Parathath SR, Mainwaring LA, Fernandez-L A, Guldal CG, Nahlé Z, Kenney AM. B-Arrestin-1 Links Mitogenic Sonic Hedgehog Signaling To the Cell Cycle Exit Machinery in Neural Precursors. *Cell Cycle*. 2010;9(19):4013–24.
101. Raghuwanshi SK, Nasser MW, Chen X, Strieter RM, Richardson RM. Depletion of β -Arrestin-2 Promotes Tumor Growth and Angiogenesis in a Murine Model of Lung Cancer. *J Immunol*. 2008;180(8):5699–706.
102. Ge L, Shenoy SK, Lefkowitz RJ, DeFea K. Constitutive protease-activated receptor-2-mediated migration of MDA MB-231 breast cancer cells requires both β -arrestin-1 and -2. *J Biol Chem*. 2004;279(53):55419–24.
103. Schaffner F, Ruf W. Tissue factor and PAR2 signaling in the tumor micro-environment. *Arterioscler Thromb Vasc Biol*. 2009;29(12):1999–2004.
104. Li TT, Alemayehu M, Aziziyeh AI, Pape C, Pampillo M, Postovit L-M, et al. -Arrestin/Ral Signaling Regulates Lysophosphatidic Acid-Mediated Migration and Invasion of Human Breast Tumor Cells. *Mol Cancer Res* [Internet]. 2009;7(7):1064–77. Available from: <http://mcr.aacrjournals.org/cgi/doi/10.1158/1541-7786.MCR-08-0578>
105. Lundgren K, Tobin NP, Lehn S, Stål O, Rydén L, Jirstrom K, et al. Stromal Expression of -Arrestin-1 Predicts Clinical Outcome and Tamoxifen Response in Breast Cancer. *JMDI* [Internet]. 2011;13(3):340–51. Available from: <http://dx.doi.org/10.1016/j.jmoldx.2011.01.009>
106. Michal AM, Peck AR, Tran TH, Liu C, Rimm DL, Rui H, et al. Differential expression of arrestins is a predictor of breast cancer progression and survival. *Breast Cancer Res Treat*. 2011;130(3):791–807.
107. Sibbering M, Courtney CA. Management of breast cancer: Basic principles. *Surg (United Kingdom)* [Internet]. 2016;34(1):25–31. Available from: <https://doi.org/10.1016/j.mpsur.2019.01.004>
108. Lima-fernandes E, Scott MGH. Arrestins as Regulatory Hubs in Cancer Signalling Pathways Arrestins as Regulatory Hubs in Cancer Signalling Pathways. 2014;(January).
109. Shenoy SK, Han S, Zhao YL, Hara MR, Oliver T, Cao Y, et al. B-arrestin1 mediates metastatic growth of breast cancer cells by facilitating HIF-1-dependent VEGF expression. *Oncogene*. 2012;31(3):282–92.
110. Gurevich V V, Gurevich E V. Synthetic biology with surgical precision: Targeted reengineering of signaling proteins. *Cell Signal* [Internet]. 2012;24(10):1899–908. Available from: <http://dx.doi.org/10.1016/j.cellsig.2012.05.012>

111. DeWire SM, Ahn S, Lefkowitz RJ, Shenoy SK. β -Arrestins and Cell Signaling. *Annu Rev Physiol* [Internet]. 2007;69(1):483–510. Available from: <http://www.annualreviews.org/doi/10.1146/annurev.physiol.69.022405.154749>
112. Povsic TJ, Kohout TA, Lef RJ. β -Arrestin1 Mediates Insulin-like Growth Factor 1 (IGF-1) Activation of Phosphatidylinositol 3-Kinase (PI3K) and Anti-apoptosis *. 2003;278(51):51334–9.
113. Wang P, Kumar P, Wang C, Fea KA. Differential regulation of class IA phosphoinositide 3-kinase catalytic subunits p110 α and β by protease-activated receptor 2 and β -arrestins. 2007;230:221–30.
114. Beaulieu J, Sotnikova TD, Marion S, Lefkowitz RJ, Gainetdinov RR, Caron MG, et al. An Akt / β -Arrestin 2 / PP2A Signaling Complex Mediates Dopaminergic Neurotransmission and Behavior. 2005;122:261–73.
115. Bunnett NW, Defea KA, Vaughn ZD, Nishijima D. The proliferative and antiapoptotic effects of substance P are facilitated by formation of a β -arrestin-dependent scaffolding complex. 2000;
116. Revankar CM, Vines CM, Cimino DF, Prossnitz ER. Arrestins Block G Protein-coupled Receptor-mediated Apoptosis *. 2004;279(23):24578–84.
117. Lefkowitz RJ, Rajagopal K, Whalen EJ. New Roles for β -Arrestins in Cell Signaling: Not Just for Seven-Transmembrane Receptors. *Mol Cell*. 2006;24(5):643–52.
118. Manuscript A. recycling and apoptosis. 2010;10(9):1286–300.
119. Kaparianos A, Argyropoulou E, Spiropoulos K. The role of Beta-arrestins in respiratory pathophysiology and tumorigenesis: going a step beyond the cell surface. *Eur Rev Med Pharmacol Sci*. 2012;16(13):1781–94.
120. Li J, Guo A, Wang Q, Li Y, Zhao J, Lu J, et al. NF- κ B directly regulates β -arrestin-1 expression and forms a negative feedback circuit in TNF- α -induced cell death. *FASEB J*. 2018;32(8):4096–106.
121. Lefkowitz RJ, Rajagopal K, Whalen EJ. New Roles for β -Arrestins in Cell Signaling: Not Just for Seven-Transmembrane Receptors. *Mol Cell* [Internet]. 2006;24(5):643–52. Available from: <http://dx.doi.org/10.1016/j.molcel.2006.11.007>
122. Fong AM, Premont RT, Richardson RM, Yu YR, Lefkowitz RJ, Patel DD. Defective lymphocyte chemotaxis in beta-arrestin2- and GRK6-deficient mice. *Proc Natl Acad Sci U S A* [Internet]. 2002;99(11):7478–83. Available from: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12032308
123. Décaillot FM, Kazmi MA, Lin Y, Ray-Saha S, Sakmar TP, Sachdev P. CXCR7/CXCR4 heterodimer constitutively recruits β -arrestin to enhance cell migration. *J Biol Chem*. 2011;286(37):32188–97.
124. Zou L, Yang R, Chai J, Pei G. Rapid xenograft tumor progression in beta-arrestin1 transgenic mice due to enhanced tumor angiogenesis. *FASEB J*. 2008;22(2):355–64.
125. Zheng K, He Z, Kitazato K, Wang Y. Selective autophagy regulates cell cycle in cancer therapy. *Theranostics*. 2019;9(1):104–25.

Kaynaklar

126. Otto T, Sicinski P. Cell cycle proteins as promising targets in cancer therapy. *Nat Rev Cancer* [Internet]. 2017;17(2):93–115. Available from: <http://dx.doi.org/10.1038/nrc.2016.138>
127. Girnita L, Shenoy SK, Sehat B, Vasilcanu R, Vasilcanu D, Girnita A, et al. β -arrestin and Mdm2 mediate IGF-1 receptor-stimulated ERK activation and cell cycle progression. *J Biol Chem*. 2007;282(15):11329–38.
128. Bastien RR, Rodríguez-Lescure Á, Ebbert MT, Prat A, Munárriz B, Rowe L, et al. PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers. *BMC Med Genomics*. 2012;5.
129. Wen DY, Lin P, Pang YY, Chen G, He Y, Dang YW, et al. Expression of the long intergenic non-protein coding RNA 665 (LINc00665) gene and the cell cycle in hepatocellular carcinoma using the cancer genome atlas, the gene expression omnibus, and quantitative real-time polymerase chain reaction. *Med Sci Monit*. 2018;24:2786–808.
130. Kühn R, Löhler J, Rennick D, Rajewsky K, Müller W. Interleukin-10-deficient mice develop chronic enterocolitis. *Cell*. 1993;75(2):263–74.
131. Benovic JL, Strassert RH, Caront MG, Lefkowitz RJ. β 3-Adrenergic receptor kinase : Identification of a novel protein kinase that phosphorylates the agonist-occupied form of the receptor. 1986;83(May):2797–801.
132. Ma L, Pei G. Beta-Arrestin Signaling and Regulation of Transcription. *J Cell Sci* [Internet]. 2007;120(2):213–8. Available from: <http://jcs.biologists.org/cgi/doi/10.1242/jcs.03338>
133. Song Q, Ji Q, Li Q. The role and mechanism of β -arrestins in cancer invasion and metastasis (Review). *Int J Mol Med*. 2018;41(2):631–9.
134. Cao Y, Zhou Y, He X, Zhou C, Cui L, Zhuang Q, et al. Overexpression of β -arrestin2 induces G1-phase cell cycle arrest and suppresses tumorigenicity in renal cell carcinoma. 2017;1729–37.
135. Hu S, Wang D, Wu J, Jin J, Wei W, Sun W. Involvement of β -arrestins in cancer progression. *Mol Biol Rep*. 2013;40(2):1065–71.
136. Sun WY, Hu SS, Wu JJ, Huang Q, Ma Y, Wang QT, et al. Down-regulation of β -arrestin2 promotes tumour invasion and indicates poor prognosis of hepatocellular carcinoma. *Sci Rep*. 2016;6(October):1–14.
137. Clay-Farrace L, Pelizon C, Santamaria D, Pines J, Laskey RA. Human replication protein Cdc6 prevents mitosis through a checkpoint mechanism that implicates Chk1. *EMBO J*. 2003;22(3):704–12.
138. Malumbres M, Barbacid M. Mammalian cyclin-dependent kinases. *Trends Biochem Sci*. 2005;30(11):630–41.
139. Beck H, Nahse-Kumpf V, Larsen MSY, O'Hanlon KA, Patzke S, Holmberg C, et al. Cyclin-Dependent Kinase Suppression by WEE1 Kinase Protects the Genome through Control of Replication Initiation and Nucleotide Consumption. *Mol Cell Biol*. 2012;32(20):4226–36.
140. Anda S, Rothe C, Boye E, Grallert B. Consequences of abnormal CDK activity in S phase. *Cell Cycle*. 2016;15(7):963–73.
141. Lapointe J, Lachance Y, Labrie Y, Labrie C. A p18 mutant defective in CDK6 binding in human breast cancer cells. *Cancer Res*. 1996;56(20):4586–9.

Kaynaklar

142. Köhler C, Koalick D, Fabricius A, Parplys AC, Borgmann K, Pospiech H, et al. Cdc45 is limiting for replication initiation in humans. *Cell Cycle*. 2016;15(7):974–85.
143. Pollok S, Bauerschmidt C, Sanger J, Nasheuer HP, Grosse F. Human Cdc45 is a proliferation-associated antigen. *FEBS J*. 2007;274(14):3669–84.
144. Han JY, Han YK, Park GY, Kim SD, Kim JS, Jo WS, et al. Bub1 is required for maintaining cancer stem cells in breast cancer cell lines. *Sci Rep*. 2015;5.
145. Yuan J, Kramer A, Matthes Y, Yan R, Spankuch B, Gatje R, et al. Stable gene silencing of cyclin B1 in tumor cells increases susceptibility to taxol and leads to growth arrest in vivo. *Oncogene*. 2006;25(12):1753–62.
146. Tan Y, Wang Q, Xie Y, Qiao X, Zhang S, Wang Y, et al. Identification of FOXM1 as a specific marker for triple-negative breast cancer. *Int J Oncol*. 2019;54(1):87–97.
147. Colak D, Nofal A, AlBakheet AB, Nirmal M, Jeprel H, Eldali A, et al. Age-Specific Gene Expression Signatures for Breast Tumors and Cross-Species Conserved Potential Cancer Progression Markers in Young Women. *PLoS One*. 2013;8(5).
148. Ding K, Li W, Zou Z, Zou X, Wang C. CCNB1 is a prognostic biomarker for ER+ breast cancer. *Med Hypotheses* [Internet]. 2014;83(3):359–64. Available from: <http://dx.doi.org/10.1016/j.mehy.2014.06.013>
149. Li TT, Alemayehu M, Aziziyeh AI, Pape C, Pampillo M, Postovit L, et al. β -Arrestin / Ral Signaling Regulates Lysophosphatidic Acid – Mediated Migration and Invasion of Human Breast Tumor Cells. 2009;7(July):1064–78.
150. Sun Y, Cheng Z, Ma L, Pei G. β -arrestin2 is critically involved in CXCR4-mediated chemotaxis, and this is mediated by its enhancement of p38 MAPK activation. *J Biol Chem*. 2002;277(51):49212–9.
151. Girnita L, Shenoy SK, Sehat B, Vasilcanu R, Girnita A, Lefkowitz RJ, et al. β -arrestin is crucial for ubiquitination and down-regulation of the insulin-like growth factor-1 receptor by acting as adaptor for the MDM2 E3 ligase. *J Biol Chem*. 2005;280(26):24412–9.
152. Suleymanova N, Crudden C, Shibano T, Worrall C, Oprea I, Tica A, et al. Functional antagonism of β -arrestin isoforms balance IGF-1R expression and signalling with distinct cancer-related biological outcomes. *Oncogene* [Internet]. 2017;36(41):5734–44. Available from: <http://dx.doi.org/10.1038/onc.2017.179>
153. Balz LM, Bartkowiak K, Andreas A, Pantel K, Niggemann B, Zanker KS, et al. The interplay of HER2/HER3/PI3K and EGFR/HER2/PLC- γ 1 signalling in breast cancer cell migration and dissemination. *J Pathol*. 2012;227(2):234–44.
154. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. *Nat Rev Mol Cell Biol*. 2001;2(2):127–37.
155. Santos-Zas I, Gurriaran-Rodriguez U, Cid-Dıaz T, Figueroa G, Gonzalez-Sanchez J, Bouzo-Lorenzo M, et al. β -Arrestin scaffolds and signa-

Kaynaklar

- ling elements essential for the obestatin/GPR39 system that determine the myogenic program in human myoblast cells. *Cell Mol Life Sci.* 2016;73(3):617–35.
156. Gonzalez DM, Medici D. Signaling mechanisms of the epithelial-mesenchymal transition. *Sci Signal.* 2014;7(344):re8.